1 H NMR spectra were collected on 600 or 400 MHz NMR spectrometers using the deuterated solvent as an internal deuterium reference. Chemical shift data are given in δ units calibrated with residual protic solvent. The multiplicity of a signal is indicated as follows: s, singlet; d, doublet; t, triplet; q, quartet; quin, quintet; m, multiplet.
13 C NMR spectra were collected on 150 or 100 MHz spectrometers with proton decoupling using the deuterated solvent as an internal carbon reference. Chemical shift data are given in δ units calibrated with residual solvent. 31 P NMR quantitative spectra were collected on 242.95 or 161.83
MHz spectrometers inverse gated proton decoupling. High-resolution mass spectra (HRMS) were collected on electrospray ionization (ESI)-or matrix assisted laser desorption ionization (MALDI)-time-of-flight (TOF) spectrometers.
Abbreviations: BMT, 5'-(benzylmercapto)-1H-tetrazole; MS, molecular sieve; dT, 2'-deoxythymidine; dC (Bz) , N 4 -benzoyl-2'-deoxycytidine; dG (Ib) , N 2 -isobutyryl-2'-deoxyguanosine, dA (Bz) , N 6 -benzoyl-2'-deoxyadenosine; NMI, N-methylimidazole; BPO, butanone peroxide; DMP, dimethylphthalate; DCA, dichloro acetic acid; THF, tetrahydrofuran; Fmoc, 9-fluorenylmethoxycarbonyl; DIPCI, diisopropylcarbodiimide; DMAP, 4-dimethylaminopyridine; COMU,
N-[(1-cyano-2-ethoxy-2-oxoethylideneaminooxy)dimethylamino(morpholino)]carbenium
hexafluorophosphate; DIPEA, diisopropylethylamine; DMT-MM, S14 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride; DBU, 1, .0]undec-7-ene; TBDMS, tert-butyldimethylsilyl; TFA, tirifluoroactic acid.
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Synthesis and characterization data
Supported dT (S3)
The titled compound was synthesized according to the reported procedure. 
5'-Phosphitylation of the Supported dT
To a solution of the supported dT S3 (132 mg, 0.10 mmol) in CH 2 Cl 2 (4 mL) stirred at r. 1H, dd, J = 27.02, 5.95 Hz), 4.201 (1H, d, J = 12.36 Hz), m), 745 (2H, m) 169.774, 163.605, 153.336, 150.447, 139.692, 135.593, 129.853, 117.429, 111.375, 111.079, 105.835, 85.069, 84.640, 84.382, 75.774, 75.515, 73.608, 69.404, 64.198, 63.540, 63.387, 58.772, 58.544, 58.467, 58.258, 43.374, 43.260, 43.145, 37.882, 37.558, 32.009, 30.398, 29.806, 29.606, 29.444, 29.234, 26.183, 24.839, 14.198, 12.663, 12.530; 31 P NMR (242.95 MHz, CDCl 3 ) δ 150.191, 149.217, 14.835, 9.691, 8.311;  IR ν max (cm -1 , KBr) 3509. 81, 3182.93, 3071.08, 2912.95, 2851.24, 2360.44, 2338.59, 1696.09, 1640.16, 1577.49, 1470.46, 1426.10, 1380.78, 1324.86, 1273.75, 1217.83, 1200.47, 1155.15, 1110.80, 1048.12, 1031.73, 974.84, 885.17, 716.43, 558.29 
General procedure for elongation of oligonucleotides
Carried out according to the reported procedure. 1 To a solution of supported oligonucleotide (1.0 mmol) in dichloromethane (88 mL) stirred at rt was added amidite monomer and 0.25 M BMT/MeCN (8.8 mL). The resulting reaction mixture was stirred at rt for 20 min, followed by the addition of 1% Ac 2 O, 1% pyridine, and 1% NMI. The resulting reaction mixture was stirred at rt for 10 min, followed by the addition of 0.67% BPO/DMP/CH 2 Cl 2 . The resulting reaction mixture was stirred at rt for 10 min, diluted with MeOH (100 mL), and collected by vacuum filtration. The residue was repeatedly washed with MeOH and dried in vacuo to
give the elongated product as a white solid.
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General procedure for deprotection of DMTr 
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5'-Phosphitylation of the supported trinucleotide 1, see Table 1 To a solution of the supported trinucleotide 1 (110 mg, 0.050 mmol) in CH 2 Cl 2 (2 mL) stirred at rt was CDCl3) δ 150. 1624, 150,083, 149,362, 149.298, 14.781, 9.502, 9.015, -1.624 --3. 
Competition experiment between alcohol and carboxylic acid, see Scheme 1
To a solution of the supported dT S4 ( 653, 170.777, 169.676, 163.213, 153.360, 150.258, 142.455, 139.927, 138.998, 135.053, 129.835, 128.495, 126.072, 122.108, 119.571, 116.335, 111.844, 105.917, 84.604, 82.641, 74.340, 73.622, 69.447, 68.844, 676.551, 62.141, 37.094, 35.265, 32.000, 30.401, 29.941, 29.798, 29.444, 29.242, 29.166, 29.108, 27.979, 27.203, 26.179, 22.760, 19.840, 14.239, 12.506 35, 3211.86, 3071.08, 2912.95, 2851.24, 2349.84, 2248.59, 1701.87, 1640.16, 1583.27, 1465.63, 1431.89, 1386.57, 1329.68, 1267.97, 1245.79, 1222.65, 1160.94, 1121.40, 997.98, 766.57, 716.43, 699.07, 671.11, 552.51 
Supported Tyr(t-Bu) (S7)
To a solution of Fmoc-Tyr(t-Bu)-OH (1.65 g, 3.6 mmol) and compound S6 (1.5 g, 2.0 mmol) in CH 2 Cl 2 (50 mL) stirred at rt was added DIPCI ( 1.6 mL, 3.6 mmol) and DMAP (180 L, 0.4 mmol). The resulting reaction mixture was stirred at rt for 2 h, diluted with MeCN (100 mL), and collected by vacuum filtration.
The residue was repeatedly washed with MeCN and dried in vacuo to give the titled compound S7 in 98% 543, 161.116, 158.703, 155.562, 154.452, 144.025, 143.872, 141.382, 131.817, 130.544, 129.998, 127.767, 127.144, 125.239, 125.201, 124.138, 120.030, 116.449, 115.827, 104.567, 99.713, 78.371, 68.260, 68.202, 66.996, 63.070, 54.845, 47.262, 32.029, 29.807, 29.760, 29.721, 29.530, 29.463, 29.377, 28.926, 26.159, 22.799, 14.229, 2.002 ; IR ν max (cm -1 , KBr) 3330. 46, 2911.99, 2861.84, 2638.14, 2465.54, 2403.83, 2319.95, 2281.38, 2253.41, 2019.10, 1895.68, 1733.69, 1617.02, 1594.84, 1510.95, 1460.81, 1382.71, 1337.39, 1293.04, 1259.29, 1181.19, 1136.83, 1036.55, 918.91, 896.74, 830.21, 780.07, 757.89, 740.53, 718.35, 640.25, 612.29, 573.72, 545.76, 500.44, 461.87, 416.55 
General procedure for coupling of peptide
To a solution of supported peptide (1.0 mmol) and Fmoc-AA-OH in THF (20 mL) stirred at rt was added COMU (1.4 mmol) and DIPEA (1.4 mmol). The resulting reaction mixture was stirred at rt for 10 min, diluted with MeCN (60 mL), and collected by vacuum filtration. The residue was repeatedly washed with MeCN and dried in vacuo to give the coupled product as a white solid.
General procedure for deprotection of Fmoc
To a solution of supported peptide (1.0 mmol) in THF (19.4 mL) stirred at rt was added DBU (600 µL). The resulting reaction mixture was stirred at rt for 5 min, diluted with MeCN (60 mL), neutralized 1 N HCl (4 mL) and collected by vacuum filtration. The residue was repeatedly washed with MeCN and dried in vacuo to give the deprotected product as a white solid.
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Tripeptide 3, Scheme S3 96, 173.10, 155.95, 144.06, 143.76, 141.26, 129.96, 127.42, 126.85, 124.87, 119.56, 114.86, 66.34, 58.45, 53.92, 53.64, 40.55, 36.25, 31.01, 24.54, 22.19, 20.50, 18.35, 17.29 MeCN/50 mM AcOH/NH 3 buffer or 50 mM AcOH/NH 3 buffer and filtered by membrane filter (0.45 µm).
The filtrate solution was dried by lyophilization. The resulting crude mixture was purified by HPLC to give the desired bioconjugates 11 or 12.
F) Deprotection and cleavage of ACSS in pentapeptide 7 conjugate Protected pentapeptide conjugates (5 µmol) was added to 5% DCA/CH 2 Cl 2 (1 mL) .The resulting mixture was stirred at rt for 5 min, diluted with MeCN (5 mL), neutralized with TEA and collected by vacuum S27 filtration. The residue was added to CH 2 Cl 2 (1 mL) and filtered by membrane filter (0.45 µm). The filtrate solution was evaporated and dried in vacuo. The crude mixture was added to 28% NH 3 aq/EtOH (3:1, v/v).
The resulting reaction mixture was stirred at 70 o C for 3 h, followed by evaporation. The residue was diluted with 50 mM AcOH/NH 3 buffer and filtered by membrane filter (0.45 µm). The filtrate solution was dried by lyophilization. The resulting crude mixture was TEA 3HF (1 mL) and DMF (1 mL). The resulting mixture was stirred at rt for 24 h, diluted with 50 mM AcOH/NH 3 buffer (1 mL) and purified by C18 column by using 20% MeCN/50 mM AcOH/NH 3 buffer as eluting solvent. The crude mixture was dried by lyophilization. The resulting crude mixture was purified by HPLC to give the desired bioconjugate 8.
Protected tripeptide conjugate
Crude product as white solid; 31 P NMR (242.95 MHz, CDCl 3 ) δ 12. 426, 11.722, 9.664, 9.069, -1.570--3.194, -5.387, -7.959 HPLC spectra are Figure 3 in the Manuscript and Figure S4 .
Protected pentapeptide conjugate
Crude product as white solid. HPLC spectra are Figure S1 and S4.
Protected lipid conjugate
Crude product as white solid. HPLC spectra are Figure S2 and S4.
Protected sugar conjugate
Crude product as white solid. 31 
Bioconjugations and deprotection, see Scheme 4
All protocol was carried out according to the procedure of pentapeptide conjugate (8).
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